COVID Guidelines – Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era
Clinical Trials – Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177 Lu-Dotatate: an analysis of the NETTER-1 study3
Basic Science – Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy
- Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice
Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences
Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas.
Surgery management for sporadic small (≤2 cm), non-functioning pancreatic neuroendocrine tumors
Baseline plasma chromogranin A levels in patients with well-differentiated neuroendocrine tumors of the pancreas
Frequent Presence of Lymphovascular Invasion in Small Rectal Neuroendocrine Tumors on Immunohistochemical Analysis.
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumours
Additional malignancies in patients with neuroendocrine tumours: analysis of the SwissNET registry
Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastroenteropancreatic Neuroendocrine Tumors and Unknown Primary Sites
Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours.
The Ki-67 labelling index and lymphatic/venous permeation predict the metastatic potential of rectal neuroendocrine tumors